An observational study of patients undergoing therapy for Chronic Hepatitis B (HBV) Infection
An Observational Study of Patients Undergoing Therapy for Chronic Hepatitis B (HBV) Infection
Sponsor: Target PharmaSolutions, Inc
Enrolling: Male and Female Patients
IRB Number: AAAS1162
U.S. Govt. ID: NCT03692897
Contact: Amanda Alonso: 212-305-3839 / aa2974@cumc.columbia.edu
Additional Study Information: The TARGET-HBV study engages an observational research design to conduct a comprehensive review of therapeutic outcomes for patients with chronic hepatitis B (HBV) who are currently taking tenofovir alafenamide (TAF) relative to those patients following other treatment regimens. The study will address important clinical questions regarding the management of HBV with TAF and other oral therapies by collecting and analyzing data from patients at academic and community medical centers. TARGET-HBV creates a robust database of real-world data regarding the natural history, management, and health outcomes related to TAF.
Investigator
Elizabeth Verna, MD
Do You Qualify?
Are you 18 years or older? Yes No
Have you been diagnosed with Hepatitis B? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Amanda Alonso
aa2974@cumc.columbia.edu
212-305-3839